GlassScriptPrepare for your visit
Fadi Hammoudeh
Pulmonary Disease · Tucson, AZ · NPI 1184861791
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$861.44
in general payments reported to CMS, 2019-2025 · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Who reported paying
General payments only, top 6 by amount.
- Veran Medical Technologies, INC. $629.63
- Mylan Specialty L.P. $125.00
- Inspire Medical Systems, INC. $54.77
- Boehringer Ingelheim Pharmaceuticals, INC. $20.60
- Insmed, INC. $17.38
- Astrazeneca Pharmaceuticals LP $11.56
Drugs and devices associated with these payments
Inspire Brinsupri
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Fadi Hammoudeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/281212/fadi-hammoudeh